These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 9737399)

  • 1. Quality of biotechnological products: derivation and characterisation of cell substrates used for production of biotechnological/biological products. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():223-34. PubMed ID: 9737399
    [No Abstract]   [Full Text] [Related]  

  • 2. Quality of biotechnological products: analysis of the expression construct in cell lines used for production of r-DNA derived protein products. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():205-8. PubMed ID: 9737397
    [No Abstract]   [Full Text] [Related]  

  • 3. Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():177-201. PubMed ID: 9737396
    [No Abstract]   [Full Text] [Related]  

  • 4. Quality of biotechnological products: stability testing of biotechnological/biological products. Annex to the ICH Harmonised Tripartite Guideline for the Stability Testing of New Drug Substances and Products.
    Dev Biol Stand; 1998; 93():211-9. PubMed ID: 9737398
    [No Abstract]   [Full Text] [Related]  

  • 5. International Conference on Harmonisation; guidance on quality of biotechnological/biological products: derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Sep; 63(182):50244-9. PubMed ID: 12269373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals (requirements for biological substances No 50).
    Dev Biol Stand; 1998; 93():141-71. PubMed ID: 9737395
    [No Abstract]   [Full Text] [Related]  

  • 7. ICH guidelines and PhEur monographs on derivation and characterisation of cell substrates used for production of biotechnological/biological products. International Conference on Harmonisation.
    Dobbelaer R
    Dev Biol Stand; 1999; 98():159-65; discussion 167. PubMed ID: 10494969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; inspection and enforcement. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Nov; 69(226):68611-88. PubMed ID: 15562555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals: application to influenza vaccine production.
    Griffiths E
    Dev Biol Stand; 1999; 98():153-7; discussion 167. PubMed ID: 10494968
    [No Abstract]   [Full Text] [Related]  

  • 10. Quality control of bovine serum used for vaccine production.
    Mareschal JC
    Dev Biol Stand; 1999; 99():61-8. PubMed ID: 10404877
    [No Abstract]   [Full Text] [Related]  

  • 11. The quality control of biotechnology products.
    Federici MM
    Biologicals; 1994 Jun; 22(2):151-9. PubMed ID: 7917231
    [No Abstract]   [Full Text] [Related]  

  • 12. Cell line banking and authentication.
    Hay RJ
    Dev Biol Stand; 1998; 93():15-9. PubMed ID: 9737372
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of biological products prepared from mammalian cell culture. Detecting viruses in cell banks.
    Dev Biol Stand; 1998; 93():129. PubMed ID: 9737388
    [No Abstract]   [Full Text] [Related]  

  • 14. An overview of animal cell substrates for biological products.
    Petricciani J; Sheets R
    Biologicals; 2008 Nov; 36(6):359-62. PubMed ID: 18674929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Status of WHO concerning continuous cell lines as substrates for the production of biologicals.
    Grachev V; Magrath D
    Dev Biol Stand; 1989; 70():215-9. PubMed ID: 2759349
    [No Abstract]   [Full Text] [Related]  

  • 16. International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1999 Aug; 64(159):44928-35. PubMed ID: 12356094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability--FDA. Notice.
    Fed Regist; 1998 Sep; 63(185):51074-84. PubMed ID: 10185809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raw materials as a source of contamination in large-scale cell culture.
    Garnick RL
    Dev Biol Stand; 1998; 93():21-9. PubMed ID: 9737373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Conference on Harmonisation; guidance on Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Jun; 70(125):37861-2. PubMed ID: 15988855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Summary and conclusion. Animal sera, animal sera derivatives and substitutes used in the manufacture of pharmaceuticals.
    Castle P; Robertson JS
    Dev Biol Stand; 1999; 99():191-6. PubMed ID: 10404890
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.